Latest Regulatory Approval News

Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.

Syntara Limited’s FY2026 results show a 7.9% revenue decline and a 13.6% increase in net loss amid significant clinical progress, including FDA backing for its lead drug amsulostat and a successful $8.8 million capital raise.

Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.

Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.

BlackWall Limited posted a $2.4 million statutory loss for FY2026, driven by operating setbacks and unrealised asset write-downs. The company suspends dividends after exhausting franking credits and proposes a share buy-back offering WOT securities in lieu of cash.

Heartland has cleared a major hurdle in its $620 million acquisition of TSB, with Toi Foundation trustees approving the sale. The merger aims to create a stronger regional challenger bank, pending shareholder and regulatory green lights.

Acrow Limited secures final ACCC approval for its AusGroup Industrial Services acquisition, clearing the path for completion on 1 September 2026 and strengthening its foothold in Australia’s civil infrastructure sector.

Nickel Industries surged to a US$74 million profit in H1 2026, driven by higher nickel prices, expanded mining quotas, and strategic HPAL investments including first nickel cathode production at ENC.

TALi Digital Limited (ASX: TD1) posted a 416% jump in revenue for FY26 but also recorded a $2.2 million loss driven by a $1.3 million impairment of its YCDI! intangible assets. The company is pursuing growth through AI-focused acquisitions and a $3.3 million capital raise.

Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) are in early talks about merging to form a larger infectious disease diagnostics entity, combining rapid pathogen detection with microbiome profiling. The proposed group would have FY2026 pro forma revenue of around A$29 million and a stronger financial footing.

Acrux Limited reported a 46% revenue increase to $6.6 million in FY26, driven by US generic product royalties and licensing milestones, while narrowing its net loss by 90%. The company is pivoting towards developing a female testosterone therapy with encouraging Phase II data and active regulatory engagement.

Neuren Pharmaceuticals reported an 8% rise in H1 2026 revenues driven by DAYBUE royalties, but profit fell 68% due to ramped-up R&D. The company declared its first ever dividend, signalling confidence amid ongoing clinical and regulatory milestones.